- Home
- AMRX vs LXP Comparison
AMRX vs LXP Comparison
Compare AMRX & LXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRX
- LXP
- Stock Information
- Founded
- AMRX 2002
- LXP 1993
- Country
- AMRX United States
- LXP United States
- Employees
- AMRX N/A
- LXP N/A
- Industry
- AMRX Biotechnology: Pharmaceutical Preparations
- LXP Real Estate Investment Trusts
- Sector
- AMRX Health Care
- LXP Real Estate
- Exchange
- AMRX Nasdaq
- LXP Nasdaq
- Market Cap
- AMRX 2.4B
- LXP N/A
- IPO Year
- AMRX N/A
- LXP 1993
- Fundamental
- Price
- AMRX $8.38
- LXP $8.65
- Analyst Decision
- AMRX Strong Buy
- LXP Buy
- Analyst Count
- AMRX 5
- LXP 3
- Target Price
- AMRX $10.80
- LXP $11.50
- AVG Volume (30 Days)
- AMRX 1.8M
- LXP 2.2M
- Earning Date
- AMRX 05-02-2025
- LXP 05-01-2025
- Dividend Yield
- AMRX N/A
- LXP 6.23%
- EPS Growth
- AMRX N/A
- LXP 59.02
- EPS
- AMRX N/A
- LXP 0.13
- Revenue
- AMRX $2,793,957,000.00
- LXP $358,458,000.00
- Revenue This Year
- AMRX $10.49
- LXP N/A
- Revenue Next Year
- AMRX $7.00
- LXP $8.16
- P/E Ratio
- AMRX N/A
- LXP $67.31
- Revenue Growth
- AMRX 16.73
- LXP 5.27
- 52 Week Low
- AMRX $5.18
- LXP $7.65
- 52 Week High
- AMRX $9.48
- LXP $10.57
- Technical
- Relative Strength Index (RSI)
- AMRX 46.15
- LXP 42.26
- Support Level
- AMRX $8.18
- LXP $8.67
- Resistance Level
- AMRX $8.95
- LXP $9.20
- Average True Range (ATR)
- AMRX 0.31
- LXP 0.19
- MACD
- AMRX -0.08
- LXP -0.06
- Stochastic Oscillator
- AMRX 23.40
- LXP 11.11
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.